Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF N486_P490del Trametinib pancreatic ductal adenocarcinoma predicted - sensitive detail...
ATM R3008C Fluorouracil + Oxaliplatin + Veliparib pancreatic ductal adenocarcinoma no benefit detail...
ATM T2333Nfs*40 Fluorouracil + Oxaliplatin + Veliparib pancreatic ductal adenocarcinoma no benefit detail...
BRAF N486_P490del LY3009120 pancreatic ductal adenocarcinoma predicted - sensitive detail...
BRAF N486_P490del LY3009120 + Trametinib pancreatic ductal adenocarcinoma sensitive detail...
BRAF V600E Cobimetinib + Gemcitabine + Nab-paclitaxel pancreatic ductal adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01647828 Phase Ib/II Nab-paclitaxel Gemcitabine Tarextumab A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Completed USA 0
NCT02042378 Phase II Rucaparib A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed USA 1
NCT02101021 Phase II Gemcitabine + Nab-paclitaxel Momelotinib Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated USA 0
NCT02109445 Phase II Gemcitabine + Nab-paclitaxel Nirogacestat Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies Terminated USA 0
NCT02241187 Phase I Cetuximab + PEGPH20 Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection Completed USA 0
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed 0
NCT02289898 Phase II Demcizumab + Gemcitabine + Nab-paclitaxel Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed USA | CAN 4
NCT02362048 Phase II Acalabrutinib Pembrolizumab ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT02501902 Phase I Nab-paclitaxel + Palbociclib Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC Completed USA 1
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02583477 Phase Ib/II AZD5069 + Durvalumab Durvalumab + Gemcitabine + Nab-paclitaxel Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Completed USA 1
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Recruiting USA 0
NCT02672917 Phase I MVT-5873 Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies Recruiting USA 0
NCT02705196 Phase Ib/II Atezolizumab + Gemcitabine + LOAd703 + Nab-paclitaxel Gemcitabine + LOAd703 + Nab-paclitaxel LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer Recruiting USA 0
NCT02732938 Phase I Gemcitabine + Nab-paclitaxel + PF-04136309 Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i) Terminated USA 0
NCT02754726 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT02810418 Phase Ib/II LMB-100 LMB-100 + Nab-paclitaxel Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Active, not recruiting USA 0
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Active, not recruiting USA 3
NCT02879318 Phase II Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma Active, not recruiting CAN 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Completed USA 0
NCT02921022 Phase 0 Gemcitabine + Nab-paclitaxel + PEGPH20 Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma Active, not recruiting USA 0
NCT02942095 Phase I Erlotinib + Ixazomib Study of Ixazomib and Erlotinib in Solid Tumors Active, not recruiting USA 0
NCT02978547 Phase II Metformin The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001) Unknown status CAN 0
NCT02981342 Phase II Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Completed USA 7
NCT02993731 Phase III Gemcitabine + Nab-paclitaxel + Napabucasin Gemcitabine + Nab-paclitaxel A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) Completed USA | CAN 18
NCT03038477 Phase II Durvalumab A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection Withdrawn USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03118349 Phase I MVT-1075 + MVT-5873 Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy Suspended USA 0
NCT03193190 Phase Ib/II Atezolizumab + BKT140 Fluorouracil + Gemcitabine + Leucovorin + Nab-paclitaxel + Oxaliplatin + Pembrolizumab Atezolizumab + PEGPH20 Atezolizumab + Cobimetinib A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Active, not recruiting USA 4
NCT03264404 Phase II Azacitidine + Pembrolizumab Azacitidine and Pembrolizumab in Pancreatic Cancer Active, not recruiting USA 0
NCT03412799 Phase I Gemcitabine + Nab-paclitaxel + SBP-101 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Active, not recruiting USA 1
NCT03415126 Phase I ERAS-007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT03415854 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel + Paricalcitol Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD) Active, not recruiting USA 0
NCT03425279 Phase Ib/II CAB-AXL-ADC CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA 0
NCT03432676 Phase II Epacadostat + Pembrolizumab Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) Withdrawn 0
NCT03435250 Phase I AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Recruiting USA 2
NCT03450018 Phase Ib/II Gemcitabine + SLC-0111 A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01) Recruiting CAN 0
NCT03496662 Phase Ib/II Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting USA 0
NCT03592888 Phase I mDC3/8-KRAS vaccine DC Vaccine in Pancreatic Cancer Recruiting USA 0
NCT03608631 Phase I iExosomes iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation Recruiting USA 0
NCT03610490 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Active, not recruiting USA 0
NCT03634332 Phase II PEGPH20 + Pembrolizumab Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC Unknown status USA 0
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Terminated USA 2
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Terminated USA 0
NCT03682289 Phase II Ceralasertib + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting USA 0
NCT03727880 Phase II Defactinib + Pembrolizumab Pembrolizumab Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA 5
NCT03806309 Phase II OSE 2101 Nivolumab + OSE 2101 Fluorouracil + Irinotecan + Leucovorin Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM) Recruiting 1
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03871959 Phase I Debio 1143 + Pembrolizumab Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) Recruiting 1
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Recruiting USA 0
NCT03979066 Phase II Atezolizumab Atezolizumab + PEGPH20 Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) Terminated USA 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Recruiting USA 4
NCT04111172 Phase II Ad5.F35-hGCC-PADRE Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies Recruiting USA 0
NCT04161755 Phase I Atezolizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + RO7198457 Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery Active, not recruiting USA 0
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA 5
NCT04257448 Phase Ib/II Gemcitabine + Nab-paclitaxel + Romidepsin Azacitidine + Gemcitabine + Nab-paclitaxel Azacitidine + Gemcitabine + Nab-paclitaxel + Romidepsin Gemcitabine + Nab-paclitaxel Durvalumab + Lenalidomide Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (SEPION) Recruiting 1
NCT04262388 Phase II Durvalumab + Oleclumab A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Withdrawn CAN 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Recruiting USA 5
NCT04431258 Phase Ib/II ABTL0812 + Fluorouracil + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) Recruiting USA 1
NCT04477343 Phase I Nivolumab + SX-682 A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT04493060 Phase II Dostarlimab-gxly + Niraparib Niraparib and Dostarlimab for Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer Recruiting USA 0
NCT04536077 Phase II CDX-1140 + CDX-301 CDX-1140 Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients Recruiting USA 0
NCT04581343 Phase I Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1) Active, not recruiting USA 0
NCT04659603 Phase II Diphenhydramine + SAR408701 SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) Recruiting USA 9
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Recruiting USA | CAN 0
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Recruiting USA 7
NCT04752696 Phase II Fluorouracil + Leucovorin + MM-398 + Onvansertib Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting USA 0
NCT04753879 Phase II Olaparib + Pembrolizumab Capecitabine + Cisplatin + Gemcitabine + Irinotecan + Nab-paclitaxel Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. Recruiting USA 0
NCT04853017 Phase Ib/II ELI-002 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor (AMPLIFY-201) Recruiting USA 0
NCT04887805 Phase II Lenvatinib + Pembrolizumab Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer Recruiting USA 0
NCT04888312 Phase Ib/II Fluorouracil + Irinotecan + JNJ-64457107 + Leucovorin + Oxaliplatin Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1) Enrolling by invitation 2
NCT04892017 Phase I DCC-3116 DCC-3116 + Trametinib A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors. Recruiting USA 0
NCT04935359 Phase III Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Recruiting USA 5
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Not yet recruiting USA | CAN 0
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA 3
NCT04989387 Phase I INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 Study of INCA 0186 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04990037 Phase I Fluorouracil + Irinotecan + Leucovorin + Nidanilimab + Oxaliplatin A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (CAPAFOUR) Recruiting 2
NCT05052723 Phase II Cabozantinib + Pembrolizumab Cabozantinib and Pembrolizumab in Metastatic Pancreas Recruiting USA 0
NCT05055323 Phase I Pyrvinium A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer Recruiting USA 0
NCT05121038 Phase Ib/II CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) Recruiting USA 0